 |
Ann Arbor, Mich. (April 18, 2007) — Dr. Daniel R. Rhodes, Compendia Bioscience Chief Scientific Officer, is presenting “Large-Scale Association Analysis of Gene Signatures Links Pathways, Mechanisms, Diseases and Drugs” during the Minisymposium at the AACR 2007 Annual Meeting in Los Angeles, CA.
Several varieties of genome-scale analysis have been applied to study human biology and disease. In the novel approach presented, an attempt to collect and integrate all relevant gene signatures in the in the oncology knowledge space for large-scale association analysis has been made. This analysis tool, Oncomine™ Concepts Map, has been built upon over 3,000 Oncomine™ gene, protein, drug, and pathway signatures, and brings understanding to high-throughput molecular profiling of cancer. This work compares signatures representing thousands of cancer types and subtypes, biological perturbations, drug treatments, manually annotated pathways and protein interaction networks, predicted regulatory networks, gene ontologies and protein families.
The utility of the approach is showcased in two studies highlighting expected results that were obtained objectively and novel hypotheses with implications for understanding and treating cancer.
- Analysis of the Myc pathway that demonstrated strong similarity of in vitro Myc signature generated in mammary epithelial cells and alternative systems, identified cancer types and subtypes displaying coordinate activation of the pathway, and detected a class of compounds capable of indirectly repressing the Myc program in vitro;
- Examination of signatures of relapse in estrogen receptor (ER) positive and negative breast cancers that suggested that largely distinct pathways mediate relapse in ER- and ER+ tumors.
Compendia Bioscience is dedicated to harnessing the global collection of high throughput molecular data to provide researchers with the data and analysis tools necessary to validate biomarker and gene target discoveries, better understand mechanisms of disease, and optimize clinical studies. Compendia Bioscience’s first product, Oncomine™ Professional, empowers oncology research by bringing advanced data analysis tools to the world’s largest cancer gene expression database, which now includes data from 18,740 microarray experiments curated from 264 independent studies. Oncomine was originally developed for academic use at the University of Michigan, and continues to be freely available to academic users. Compendia Bioscience was founded in 2006 to extend Oncomine to the commercial sector, and is headquartered in Ann Arbor, Michigan.
 media@compendiabio.com
|
|
